Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?

Eftekhar et al., medRxiv, doi:10.1101/2021.01.16.21249941
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 172 hospitalized patients, 83% treated and HCQ+AZ and 17% with HCQ, not finding a significant difference in QTc prolongation, but recommending careful monitoring for the use of HCQ+AZ; especially in males, patients with high-risk Tisdale score, and in patients who have baseline QTc interval ≥ 450 milliseconds.
Eftekhar et al., 26 Jan 2021, preprint, 6 authors.
This PaperHCQAll
Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?
Seyed Parsa Eftekhar, Sohrab Kazemi, Mohammad Barary, Mostafa Javanian, Soheil Ebrahimpour, Naghmeh Ziaei
Background: Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause Torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin. Methods: This was a retrospective cohort study. 172 patients with COVID-19 included, hospitalized at hospitals of Babol University of Medical Sciences between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment. Results: 83.1% of patients received hydroxychloroquine plus azithromycin vs 16.9% of patients who received only hydroxychloroquine. The mean age of patients was 59.2 ± 15.4. The mean of post-treatment QTc interval in the monotherapy group was shorter than the mean of post-treatment QTc interval in the combination therapy group but it had no significant statistical difference (462.5 ± 43.1 milliseconds vs 464.3 ± 59.1 milliseconds; P = 0.488). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline QTc ≥ 450 milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, 14 patients did not continue therapy after 4 days. Conclusion: Hospitalized patients treated with hydroxychloroquine with or without azithromycin, had no significant difference in prolongation of QT interval and outcome. But the number of patients with prolonged QT intervals in this study emphasizes careful cardiac monitoring during therapy; especially in high-risk patients.
Ethical Approval This study has been approved by the ethics committee of Babol University of Medical Sciences (Babol, Iran).
Bouchaud, Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base, Malar J
Chen, The SARS-CoV-2 Vaccine Pipeline: an Overview, Curr Trop Med Rep
Curtis, Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients, The American Journal of Medicine
Drici, Clément, Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome, Drug Saf
Giudicessi, Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19), Mayo Clin Proc
Huang, Azithromycin-induced torsade de pointes, Pacing Clin Electrophysiol
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Li, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, N Engl J Med
Li, Updated Approaches against SARS-CoV-2, Antimicrob Agents Chemother
Marquardt, Albertson, Treatment of hydroxychloroquine overdose, The American Journal of Emergency Medicine
Mercuro, Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease
Ray, Azithromycin and the Risk of Cardiovascular Death, New England Journal of Medicine
Roden, Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment, Journal of the American College of Cardiology
Roden, Predicting drug-induced QT prolongation and torsades de pointes, J Physiol
Rosenberg, Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Saleh, The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection, Circulation: Arrhythmia and Electrophysiology
Samarendra, QT Prolongation Associated with Azithromycin/Amiodarone Combination, Pacing and Clinical Electrophysiology
Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nature Reviews Rheumatology
Selzer, Wray, Quinidine Syncope, Circulation
Shah, A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19), Int J Rheum Dis
Tang, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, Bmj
Tang, On the origin and continuing evolution of SARS-CoV-2, Natl Sci Rev, doi:10.1093/nsr/nwaa036
Teng, Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System, Int J Med Sci
Wang, A novel coronavirus outbreak of global health concern, Lancet
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Yang, Azithromycin Causes a Novel Proarrhythmic Syndrome, Circulation: Arrhythmia and Electrophysiology
Yao, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Yap, Camm, Drug induced QT prolongation and torsades de pointes, Heart
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop